Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:ALECNASDAQ:CCCCNASDAQ:ENTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsALECAlector$1.03-2.4%$1.20$0.87▼$6.78$102.49M0.76809,673 shs693,367 shsCCCCC4 Therapeutics$1.50+6.0%$1.71$1.09▼$7.66$106.16M3.11.41 million shs2.35 million shsENTAEnanta Pharmaceuticals$5.07+0.4%$5.74$4.09▼$17.24$108.18M0.81286,543 shs116,681 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%-7.72%-7.72%+5.42%ALECAlector-9.48%-7.08%+2.94%-42.93%-80.26%CCCCC4 Therapeutics-12.96%-10.76%+7.63%-61.37%-78.99%ENTAEnanta Pharmaceuticals-7.17%-12.78%+6.77%-0.39%-65.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti PharmaN/AN/AN/AN/AN/AN/AN/AN/AALECAlector3.5595 of 5 stars3.11.00.04.52.81.70.6CCCCC4 Therapeutics2.533 of 5 stars3.32.00.00.03.42.50.6ENTAEnanta Pharmaceuticals4.2132 of 5 stars3.41.00.04.72.74.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideALECAlector 2.14Hold$3.50241.46% UpsideCCCCC4 Therapeutics 2.60Moderate Buy$12.50736.12% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25240.17% UpsideCurrent Analyst Ratings BreakdownLatest ACST, ENTA, ALEC, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025ALECAlectorMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight$3.00 ➝ $1.502/27/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/14/2025CCCCC4 TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold2/11/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.00 ➝ $21.002/11/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AALECAlector$100.56M1.02N/AN/A$1.41 per share0.73CCCCC4 Therapeutics$35.58M2.98N/AN/A$4.07 per share0.37ENTAEnanta Pharmaceuticals$66.59M1.62N/AN/A$5.24 per share0.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%5/14/2025 (Estimated)CCCCC4 Therapeutics-$132.49M-$1.51N/AN/AN/A-313.35%-42.45%-27.55%5/14/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%N/ALatest ACST, ENTA, ALEC, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ALECAlector-$0.46N/AN/AN/A$4.25 millionN/A5/14/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 millionN/A2/27/2025Q4 2024CCCCC4 Therapeutics-$0.44-$0.49-$0.05-$0.49$4.43 million$5.18 million2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 million2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AALECAlectorN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86ALECAlectorN/A3.293.29CCCCC4 TherapeuticsN/A6.316.31ENTAEnanta PharmaceuticalsN/A5.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%ALECAlector85.83%CCCCC4 Therapeutics78.81%ENTAEnanta Pharmaceuticals94.99%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%ALECAlector9.10%CCCCC4 Therapeutics8.55%ENTAEnanta Pharmaceuticals13.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableALECAlector27099.99 million89.02 millionOptionableCCCCC4 Therapeutics15071.01 million64.55 millionOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableACST, ENTA, ALEC, and CCCC HeadlinesRecent News About These CompaniesEnanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to AnalystsMay 5 at 6:13 PM | insidermonkey.comEnanta Pharmaceuticals (ENTA) Projected to Post Earnings on MondayMay 4 at 1:37 AM | americanbankingnews.com1,038,000 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Purchased by RA Capital Management L.P.May 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Caligan Partners LPMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $492,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from AnalystsMay 3, 2025 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Has $938,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 30, 2025 | marketbeat.comMarshall Wace LLP Increases Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 26, 2025 | marketbeat.comFederated Hermes Inc. Trims Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 21, 2025 | marketbeat.comWhy Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.48%April 15, 2025 | aaii.comTrexquant Investment LP Acquires 67,040 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 14, 2025 | marketbeat.comPrudential Financial Inc. Lowers Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 13, 2025 | marketbeat.comWhy Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 7.51%April 13, 2025 | aaii.comEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025April 8, 2025 | businesswire.comEnanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to ImmunologyMarch 29, 2025 | investing.comEnanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 17, 2025 | businesswire.comEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV SymposiumMarch 12, 2025 | finance.yahoo.comEnanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlookFebruary 17, 2025 | msn.comWith Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their ReturnsFebruary 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentFundamentally Sound, These 5 Stocks Sold Off AnywayBy Thomas Hughes | April 23, 2025View Fundamentally Sound, These 5 Stocks Sold Off AnywayTop 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing MarketOil Prices Are Tanking—These 3 Plays Could Fuel Your GainsBy Gabriel Osorio-Mazilli | April 9, 2025View Oil Prices Are Tanking—These 3 Plays Could Fuel Your Gains3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside ACST, ENTA, ALEC, and CCCC Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Alector NASDAQ:ALEC$1.02 -0.03 (-2.38%) Closing price 03:59 PM EasternExtended Trading$1.06 +0.03 (+2.93%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.C4 Therapeutics NASDAQ:CCCC$1.50 +0.09 (+6.03%) Closing price 03:59 PM EasternExtended Trading$1.54 +0.04 (+2.68%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$5.07 +0.02 (+0.42%) Closing price 03:59 PM EasternExtended Trading$5.07 0.00 (-0.02%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
